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Abstract The G870A polymorphism in the exon 4/intron 4
boundary of CCND1 gene is thought to influence the genera-
tion of two mRNAs (cyclin D1a and cyclin D1b). The BA^
allele codes for a truncated variant, cyclin D1b, which may
have higher transforming activity. Herein, the tumor relevance
of G870A polymorphism, the association between cyclin D1
variant expression and G870A genotype, and the oncogenic
potential of cyclin D1 variants in HBV-related hepatocellular
carcinoma (HCC) were examined. We found that there is no
significant difference of G870A distribution among the HCC,
chronic HBV (CHB) infection, cirrhotic CHB, and healthy
control groups. Stratification analysis revealed that in younger
patients (ages≤50), cirrhotic CHB patients with AA genotype
had an increased risk of developing HCC with odds ratio of
1.943 (95 % CI 1.022–3.694, p=0.0411) as compared with
AG/GG genotypes. The two variants were both transcripted
from BA^ and BG^ alleles, and neither cyclin D1a nor D1b
production was influenced by G870A genotype in HCC. The
expression of both cyclins D1a and D1b decreased in HCC
tissues (p=0.003, p=0.005), while increased in adjacent
nontumor tissues as compared with normal liver tissues (p=
0.045, p=0.034). Overexpression of cyclin D1a or D1b could
promote the cell proliferation and cell-cycle progression in
Huh-7 and LO2 cell lines. Collectively, our data suggest that
G870A polymorphism has only very limited predictive value
for HBV-related HCC. Both cyclins D1a and D1b could pro-
mote cell proliferation, which might contribute to the potential
oncogenic role of cyclin D1 variants during the precancerous
cirrhotic stage of hepatocarcinogenesis.
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Introduction
Hepatocellular carcinoma (HCC) is the third cause of cancer-
related death worldwide [1] and the 5-year survival rate is only
5 % without treatment [2]. The pathogenesis of HCC is char-
acterized by sequential events including chronic inflamma-
tion, hepatocyte hyperplasia, and ultimately malignant trans-
formation [3]. In China, the major risk factor for HCC is the
chronic hepatitis B virus (HBV) infection and subsequent he-
patic cirrhosis [4]. Although the surgical excision is still the
most effective treatment so far, most HCC patients are diag-
nosed at late stage and cannot be treated surgically. Therefore,
identification of more sensitive and specific early biomarkers
associated with the increased risk of HCC is crucial for im-
proving HCC management.
Perturbations in the regulation of the core cell-cycle ma-
chinery are frequently observed in human cancers. As a key
regulator of G1 reentry and progression, cyclin D1 is one of
the most frequently altered cell-cycle factors in cancers [5].
Cyclin D1 is encoded by the CCND1 gene which generates
two alternative splice variants (cyclin D1a and cyclin D1b)
with different coding sequences. Cyclin D1a is the common
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isoform containing all five exons, while cyclin D1b derives
from retention of intron 4 and contains a premature termina-
tion. This structural difference of cyclin D1b renders it to
localize in the nucleus through the cell cycle, which may in-
crease its oncogenic potency [6]. G870A polymorphism at the
splice donor site of the exon 4/intron 4 boundary, which is
thought to affect the production of cyclin D1a and cyclin
D1b, was identified as a predictor for increased cancer risk
[7–10]. Furthermore, upregulation of cyclin D1b has been
observed in several cancers including colorectal cancer, pros-
tate cancer, mantle cell lymphoma, and nonsmall cell lung
cancer [11–13], and the change in cyclin D1b/cyclin D1a ratio
might lead to unleashed growth of cancer cells [14]. However,
contradictory data regarding the polymorphism, D1 variant
expression, and correlation with cancer risk have also been
reported [15, 16]. Thus, the regulation of alternative splicing
of CCND1 variants might be tissue and race specific.
To date, there is little evidence regarding the role of
CCND1 G870A in HCC susceptibility of patients with chron-
ic HBV infection. In addition, the influence of G870A geno-
type on the production of cyclin D1 variants and the oncogen-
ic potential of both cyclin D1 variants in HBV-related HCC
are not fully understood. In this study, we performed a
genotyping analysis in a population-based case–control study
with a large cohort, including 238 HBV-related HCC patients,
243 chronic hepatitis B (CHB) patients, 236 cirrhotic CHB
patients, and 181 healthy controls. Furthermore, the expres-
sion of cyclins D1a and D1b in HCC tissues and the roles of
these variants in regulating the cell proliferation were also
determined. Our study here provided first evidence that G/A
polymorphism is not a strong predictor of the HBV-related
HCC risk in Chinese population.
Materials and methods
Study population
A total of 717 patients from Youan Hospital in Beijing (Octo-
ber 2009 to December 2011) were enrolled in the case–control
study. To avoid the selection bias caused by ethnics, all pa-
tients studied were Han Chinese, comprising 243 patients with
CHB, 236 patients with cirrhotic CHB, and 238 patients with
HCC. The criteria for the diagnosis of CHB group were
HBsAg positive, HBV-DNA positive, anti-HBc positive, and
the course of disease is more than 6 months, negative for anti-
HCVand anti-HIV. Under the premise of compliance with the
diagnosis of chronic hepatitis B, the group of cirrhotic CHB
patients had persistent or intermittent elevated ALT/AST
levels, without evidence of decompensation, the presence of
portal venous hypertensive symptoms, such as hypersplenism
and mild oesophagogastric varicosity, without variceal bleed-
ing, ascites, or hepatic encephalopathy, and with histological
changes of fibrosis F4 by liver biopsy using the Metavir scor-
ing system. HCC patients were all HBsAg positive and diag-
nosed by ultrasonography and computed tomography and
were confirmed by biopsy during liver transplantation or au-
topsy. In addition, a total of 181 cases of healthy control pop-
ulation were recruited from a health checkup project per-
formed by Beijing Center for Disease Prevention and Control,
who did not have a history of liver disease, had no serological
evidence of hepatitis B or C virus infection, and without a
known history of cancer or genetic diseases.
Another cohort contains 45 pairs of matched primary HCC
tumor tissue samples and adjacent nontumor tissue samples
which were obtained from patients who underwent routine
curative surgery at Henan Tumor Hospital in Zhengzhou, He-
nan Province of China. All patients were serum HBsAg or
HBV DNA positive, and all were histologically diagnosed
with liver cirrhosis. None of them has been pretreated with
radiotherapy or chemotherapy prior to surgery. Additionally,
disease-free liver tissues (n=11) were obtained from liver do-
nors in the same hospital. All these tissues were snap-frozen in
liquid nitrogen until examination.
The study protocol was approved by the institute ethics
committee, and informed consent was obtained from all pa-
tients and donors before the start of study.
Genomic DNA extraction and CCND1 G870A genotyping
Genomic DNA was extracted from 2 ml blood sample by
using a commercially available DNA extraction kit (Tiangen
Genomic DNA Kit; Tiangen Biotech, Beijing, China). All
DNA samples were frozen at −20 °C until use. The CCND1
G870A polymorphism was determined by the Taqman® SNP
Genotyping Assay (Life Technologies, Beijing, China) using
the 7300 real-time polymerase chain reaction (PCR) system
(Applied Bio Systems, USA). About 10 % of samples geno-
typed with Taqman SNP genotyping assay were further con-
firmed by the sequencing method.
RNA isolation and real-time quantitative RT-PCR
Total RNAwas extracted from the snap-frozen liver tissues or
HCC cell lines with TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) and reverse-transcribed with SuperScript® III
RT-PCR kits (Invitrogen, Grand Island, NY, USA), according
to manufacturer’s protocol. Quantitative RT-PCR was per-
formed to measure the expression levels of cyclin D1a and
cyclin D1b using Roche light-cycle 480 sequence detection
systems (Roche,Mannheim, Germany), according to the man-
ufacturer’s instructions. Primer sequences used for detection
of cyclin D1a were forward: 5′-TGGTGAACAAGCTCAA
GTGGAACC-3′ and reverse: 5′-GTGAGGCGGTAGTAGG
ACAGGAAG-3′. Primer sequences used for detection of cy-
clin D1b were forward: 5′-AACAGATCATCCGCAAACAC
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GC-3′ and reverse: 5′-GCCTGGGACATCACCCTCACTT-
3′. Amplification of the housekeeping gene CTBP1 was per-
formed to normalize the expression levels of cyclin D1a and
cyclin D1b. Primer sequences used for CTBP1 were forward:
5′-TTCACCGTCAAGCAGATGAGAC-3′ and reverse: 5′-
CTGGCTAAAGCTGAAGGGTTCC-3′.
Clone sequencing of cyclin D1a and cyclin D1b
The complimentary DNA (cDNA) of human HCC cell lines
(Huh-1 and Huh-7) were used for PCR assay by using the
specific primers of cyclin D1a or cyclin D1b. Both PCR-
amplified fragments for cyclin D1a and cyclin D1b
encompassed the exon 4/intron 4 boundary. The primer se-
quences of cyclin D1a was forward: 5′-CAAACAGATCAT
CCGCAAACACG -3′ and reverse: 5′-AAGCCTGGTCCA
CCTCCTCCTC-3′. Primer sequences used for cyclin D1b
were forward: 5′-GGAGAACAAACAGATCATCCGCAA
AC-3′ and reverse: 5′-GCCTGGGACATCACCCTCACTT
AC-3′. After PCR amplification, the PCR products of cyclin
D1a or cyclin D1b were purified and cloned into TA vector
and transformed into Escherichia coli Trans-5α chemically
competent cells. Cell clone was randomly picked up and
sequenced.
Western blot assay
Protein was extracted from the snap-frozen liver tissues and
cell lines by using the lysis buffer [50 mM HEPES (pH 7.4),
1.5 mM EDTA, 150 mM NaCl, 10 % Glycerol, 10 mM NaF,
1 mM Na3VO4, 0.5 mM DTT, 1 % Triton X-100, and 1 %
Protease Inhibitor Cocktail (P8340, Sigma)]. Protein lysates
(30 μg each) were separated by 15 % sodium dodecyl sulfates
polyacrylamide gels and transferred onto nitrocellulose mem-
branes (Bio-Rad, USA). After blocking, membranes were in-
cubated with primary antibodies against cyclin D1, Flag tag or
tubulin (MBL, Aichi, Japan), overnight at 4 °C and then with
the secondary antibodies conjugated with Cy5.5 (Bucking-
hamshire, UK) for 2 h in room temperature. Finally, the pro-
tein–antibody complexes were visualized using the Odyssey
Imager (LI-COR Biosciences, Lincoln, NE, USA).
Cell culture and transfection
The human HCC cell line Huh-7 and human normal hepatic
cell line LO2 were maintained in Dulbecco’s modified Eagle
medium supplemented with 10 % fetal bovine serum (Gibco,
Carlsbad, CA, USA). Cells were transfected with the pFlex
vector, pFlex-cyclin D1a, or pFlex-cyclin D1b by using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA, USA), according
to the manufacturer’s instructions.
CCK-8 cell proliferation assay
Cells were seeded in 96-well plates at 2×103 cells/well. Then
every day for a total of 5 days, 10 μl of CCK-8 solution
(Dojindo Laboratories, Rockville, MA, USA) was added into
each well and incubated for 1 h. The number of cells per well
was measured by the absorbance at 450 nm at the indicated
time points, according to the manufacturer’s instructions.
Flow cytometry assay
Flow cytometry assay was used to detect the cell cycle. In
brief, cells were washed with phosphate-buffered saline
(PBS) twice then resuspended in 2 ml 75 % ethanol and fixed
overnight. The fixed cells were resuspended in propidium
iodine (PI) solution containing 50 μg/ml RNaseA (Sigma,
USA) and incubated at 37 °C for 30 min in the dark. Then
the fluorescence of the PI-labeled cells was measured using a
flow cytometer (FACSCalibur, BD Biosciences, San Jose,
CA, USA).
Statistical analyses
Hardy–Weinberg equilibrium (HWE) in healthy control pop-
ulation was assessed by the Pearson χ2 test. Two-way χ2 test
and logistic regression analysis were used to compare the dif-
ferences between CCND1 G870A genotype frequencies and
allele frequencies in all groups, and the statistical analysis was
accomplished via the Statistical Analysis System (SAS 9.1 TS
level 1 M3, Cary, NC, USA). Analysis of variance (ANOVA)
test was used to analyze the differences of cyclin D1 expres-
sion levels among tumor, nontumor, and normal groups. Lin-
ear correlation analysis was carried out to analyze the associ-
ation between cyclins D1a and D1bmessenger RNA (mRNA)
expression. The differences of the cyclin D1 protein level in
different groups were analyzed by Student’s t test. In all cases,
a p value of less than 0.05 was considered significant.
Results
Demography of the study population
The gender distribution among CHB, cirrhotic CHB, HCC
and healthy groups showed no differences by the χ2 test.
However, the age distribution showed a significant increase
in HCC patients and cirrhotic CHB patients (53.7±9.4 and 50
±9.8 years, respectively), compared to CHB patients and
healthy controls (38±13.2 and 34.5±7.9 years, respectively)
in our case population.Wewere unable to obtain a goodmatch
in age factor, because the development of liver cirrhosis and
tumor is a chronic progressive course, and the average age of
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the cirrhotic CHB and HCC patients increased with the aggra-
vation of disease.
Association of G870A polymorphism with HCC risks
The CCND1 G870A genotype in all subjects was detected by
Taqman SNP-genotyping assay, and the association between
G870A polymorphism and the risk of HCC were analyzed.
First, we performed the test of Hardy–Weinberg equilibrium
in our control population. We found that the distribution of
G870A genotype in healthy control group was consistent with
the Hardy–Weinberg equilibrium, suggesting that there was
no population stratification and no sampling bias. Next, we
analyzed the correlation between the G870A polymorphism
and the susceptibility of HCC in the CHB and cirrhotic CHB
groups which all have the background of HBV infection. As
shown in Table 1, after adjusted for age and gender by logistic
regression analysis, neither the genotype nor allele distribution
showed significant difference between HCC and CHB group
(p=0.5969 and p=0.5945, respectively) or between HCC
group and cirrhotic CHB groups (p=0.1311 and p=0.136,
respectively). Similar to the above result, no significant differ-
ence of the genotype and allele distribution were observed
between HCC and healthy control groups (p=0.7309 and
p=0.442, respectively).
We next examined the association between the G870A
polymorphism and the HCC risk in the subgroups of the par-
ticipants based on age, gender, and clinically relevant factors.
When subgroup analyses were performed by gender, HBV
genotype, serum HBV DNA, ALT, or AST levels, no statisti-
cal difference of the G870A distribution was observed among
any subgroups of CHB, cirrhotic CHB, and HCC groups
(Table S1). However, the stratification analysis by age re-
vealed that the distribution of G870A genotype and allele
between younger HCC subgroups and younger cirrhotic
CHB subgroups (ages≤50) were slightly different (p=
0.0547 and p=0.0572, respectively). Consistent with this re-
sult, when compared with the combined 870 AG/GG variant
genotypes, cirrhotic CHB patients with the AA genotype had
a 1.943-fold odds ratio of developing HCC (95 % CI: [1.022,
3.694], p=0.0411) (Table 2). These findings indicated that the
G870A polymorphism was, to some extent, associated with
the HCC risk in this subgroup.
Association of G870A genotype with cyclins D1a and D1b
expression
Previous studies have provided evidence that G870A poly-
morphism may influence the expression levels of cyclin D1a
and D1b [17, 18]. To address the contribution of G870A ge-
notype to the production of cyclin D1 isoforms in HCC, we
used two independent approaches. Initially, we sequenced the
G870A polymorphism in the HCC tissues and compared the
expressions of cyclin D1a or cyclin D1b in AA and GG ge-
notype tissues. The results showed that in both HCC tumor
and nontumor tissues, the expression of cyclin D1a had no
significant difference between AA and GG genotype tissues
(p=0.6730 and p=0.8742, respectively; Fig. 1a). Similar re-
sults were obtained from cyclin D1b expression (p=0.5054
and p=0.2345, respectively; Fig. 1b). These results suggested
that neither cyclin D1a nor D1b production was influenced by
G870A genotype in HCC. To support this notion, we then
examined the distribution of BA^ or BG^ alleles in cyclin
D1a and cyclin D1b transcripts by clone sequencing analysis
in human HCC cell lines Huh-1 and Huh-7, which were iden-
tified as AG heterozygous at the 870 locus by genotyping. For
this experiment, the fragment of cyclin D1a or cyclin D1b
containing 870 locus was amplified from the cDNA of Huh-
1 and Huh-7 cell lines by PCR assay with the specific primers
of each variant. After PCR amplification, the PCR products
were cloned into TA vector and a total of 20 clones of each
transcript were randomly picked up for sequencing. If A allele
promoted cyclin D1b production, we predicted that the cyclin
D1a transcript from AG heterozygous cells should contain
more G allele and cyclin D1b transcript should contain more
A allele. However, the clone sequencing analysis failed to
detect the preference of A allele for cyclin D1b transcript since
both cyclin D1a and cyclin D1b transcripts had more G alleles
than A alleles in these AG heterozygous cells. Instead, in these
two cells, the percentage of clones with G allele was higher
Table 1 Comparison of CCND1 G870A genotype and allele frequencies among cases and controls
Groups AA (%) AG (%) GG (%) p Valuea OR (95 % CI)b A allele (%) G allele (%) p Valuea OR (95 % CI)
Healthy control 56 (30.9) 91 (50.3) 34 (18.8) 0.7309 0.582 [0.222,1.524] 203 (56.08) 159 (43.92) 0.442 1.116 [0.848,1.469]
CHB 67 (27.60) 117 (48.1) 59 (24.3) 0.5969 1.078 [0.671,1.732] 251 (51.65) 235 (48.35) 0.5945 0.934 [0.725,1.202]
Cirrhotic CHB 53 (22.5) 123 (52.1) 60 (25.4) 0.1311 0.851 [0.556,1.302] 229 (48.52) 243 (51.48) 0.136 0.824 [0.638,1.063]
HCC 67 (28.15) 120 (50.42) 51 (21.43) – – 254 (53.36) 222 (46.64) – –
CHB chronic hepatitis B virus infection, HCC hepatocellular carcinoma
a Pearson χ2 test
b Adjusted for age and gender by logistic regression analysis. GG and GA genotypes were used as reference
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than that with A allele in both cyclins D1a and D1b transcripts
(Table 3). Taken together, these findings suggested that the
two variants of cyclin D1 were both transcripted from A and
G alleles, while G allele may have higher transcript efficiency
than A allele in liver tissues.
Expression of cyclins D1a and D1b in paired HCC tissues
Since the cyclin D1b has been shown to have enhanced onco-
genic functions when compared with the full-length D1a, we
considered whether the expression of cyclin D1b and cyclin
D1a or the relative abundance of each variant were dysregu-
lated in HBV-related HCC. We applied a real-time qRT-PCR
assay to assess the mRNA expression levels of both variants in
an independent cohort of 45 pairs HBV-related HCC tissues
and 11 normal liver tissues. As shown in Fig. 2a, the expres-
sion level of cyclin D1a was significantly decreased in tumor
tissues as compared with the adjacent nontumor cirrhotic tis-
sues (p=0.003). Interestingly, the cyclin D1a expression in the
adjacent nontumor cirrhotic tissues was higher than that in
normal liver tissues (p=0.045). Likewise, the cyclin D1b ex-
pression in tumor tissues was also significantly lower than that
in nontumor cirrhotic tissues (p=0.005), which also showed a
potential upregulation as compared with normal tissues (p=
0.0343; Fig. 2b). We then assessed the relative abundance of
each variant by comparing the cyclin D1b/D1a ratio among
tumor, nontumor, and normal liver tissues. We found that the
cyclin D1b/D1a ratio had no difference in these three tissue
groups (Fig. 2c).
Next, we compared the relative expression levels between
these two splice variants in the tumor, nontumor, or normal
liver tissues after evaluating the efficiency and specificity of
both primers (data not shown). We found that the mean
mRNA expression level of cyclin D1a was significantly
higher than cyclin D1b in tumor tissues (p<0.0001). Like-
wise, similar results were obtained in nontumor tissues and
normal liver tissues (p<0.0001; Fig. 2d). These data sug-
gested that the cyclin D1a variant was the major transcript of
CCND1 gene in liver tissues. To support this notion, we de-
tected the cyclin D1 protein level in 14 pairs of HCC tissues
by Western blot assay. Since the cyclin D1 antibody used for
Western blot assay is generated from a synthetic peptide cor-
responding to full length of recombinated cyclin D1a, it can
react with both cyclins D1a and D1b. However, we only ob-
served the 36 kDa cyclin D1a in these pairs of HCC tissues
and did not observe the 34 kDa cyclin D1b, probably due to
the relatively low expression of cyclin D1b in liver tissues.
When we compared the cyclin D1a protein level in HCC
tumor tissues to their adjacent nontumor cirrhotic tissues, 9
of 14 (64.28 %) tumor tissues showed lower cyclin D1a ex-
pression, which is consistent with its lower mRNA level in
HCC tumor tissues (Fig. 2e).
Table 2 Stratification analysis of
cyclin D1 G870A polymorphism
and HCC risk in HCC and
cirrhotic CHB groups (ages≤50)
Groups GG+AG AA p Valuea OR (95 % CI)b
Cirrhotic CHB 95 (79.8 %) 24 (20.2 %) 0.0411 1.943 [1.022,3.694]
HCC 55 (67.1 %) 27 (32.9 %) – –
a Pearson χ2 test
b Adjusted for age and gender by logistic regression analysis. GG and GA genotypes were used as reference
Fig. 1 The effect of G870A genotype on the expression of cyclin D1
variants in HCC tissues. The expression of cyclin D1 variants in 17
genotyped HCC tissues was detected by real-time PCR. The expression
of cyclin D1a (a) or D1b (b) in HCC tissues with AA genotype (n=9) was
compared to GG genotype (n=8). The housekeeping gene CTBP1 was
used to normalize the expression levels of cyclin D1a and cyclin D1b.
Each sample was tested in triplicate in two separate experiments
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Correlation between cyclins D1a and D1b expression
in HCC tissues
As cyclins D1a and D1b are transcribed from the same gene, it
is critical to determine whether the expression of cyclins D1a
and D1b is coupled or independent factors in HCC. To address
this question, we analyzed the correlation between cyclins
D1a and D1b mRNA levels by using Pearson correlations
analysis. As shown in Fig. 3a, the level of cyclin D1b had a
significant linear correlation with cyclin D1a level in HCC
tumor tissues (r=0.7466, p<0.0001). Likewise, the level of
cyclin D1b also had a linear correlation with cyclin D1a level
in the nontumor tissues (r=0.33, p=0.027), but it is weaker
than that in HCC tumor tissues (Fig. 3b). These findings dem-
onstrated that the expression of cyclin D1b might be deter-
mined in parallel on the same quantitative platform of cyclin
D1a.
Effect of cyclin D1a or cyclin D1b on cell proliferation
To investigate whether both cyclins D1a and D1b could affect
the cell proliferation, we transiently transfected the cyclins
D1a and D1b expression plasmids into HCC cell line Huh-7
and normal hepatic cell LO2.Western blot assay demonstrated
the ectopic expression of Flag-tagged cyclins D1a and D1b
protein in these cells (Fig. 4a). We then performed a CCK-8
cell proliferation assay to access the roles of both variants in
Table 3 Clone sequencing analysis of cyclins D1a and D1b in Huh-1
and Huh-7 cells
Cell lines D1 transcripts (n=20) A allele G allele
Huh-1 Cyclin D1a 6 (30 %) 14 (70 %)
Cyclin D1b 4 (20 %) 16 (80 %)
Huh-7 Cyclin D1a 10 (50 %) 10 (50 %)
Cyclin D1b 3 (15 %) 17 (85 %)
Fig. 2 Expression levels of both cyclin D1 variants in paired HCC
tissues. Total RNA were prepared from 45 paired HCC tissues and 11
normal liver tissues. The expression of both cyclin D1 variants was
quantitated by qRT-PCR and normalized to CTBP1. Each sample was
tested in triplicate in two separate experiments. a The comparison of
cyclin D1a expression levels among the HCC tumor, adjacent nontumor
and the normal liver tissues. ANOVA test was used to analyze the differ-
ence of cyclin D1a expression levels among these groups. b The
expression of cyclin D1b was compared as in (a). c Ratio of cyclin D1b
versus cyclin D1a was compared as in (a). d The difference between
cyclin D1a and cyclin D1b expression in the HCC tissues, adjacent
nontumor tissues or the normal liver tissues. ANOVA test was used to
analyze the difference of cyclin D1 expression levels among these groups.
e The expression of cyclin D1a protein in 14 paired HCC tissues was
detected by Western blot assay. Tubulin was used as an internal loading
control in each lane. T tumor tissue, NT nontumor tissue
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cell growth. As shown in Fig. 4b, overexpression of both
cyclins D1a and D1b could obviously promote cell prolifera-
tion in Huh-7 and LO2 cell lines as compared to their indicat-
ed vector control. Next, we measured the effects of cyclins
D1a and D1b on the cell-cycle distribution. Consistent with
the increased cell growth, both variants could reduce the cells
in G0/G1 phase but increase cells in S phase (Fig. 4c). These
results suggested that both cyclins D1a and D1b could pro-
mote cell proliferation via accelerating the cell-cycle progres-
sion. However, in both Huh-7 and LO2 cells, no difference of
cell proliferation and cell-cycle distribution was found be-
tween the cyclins D1a and D1b transfected cells.
Discussion
Although a number of studies have described that the CCND1
870A allele is associated with susceptibility to various tumors
[7–10], results of recent meta-analysis indicated that CCND1
G870A polymorphism is a potential risk factor only in the
development of brain, lung, breast, and colorectal cancers
[10, 19–22]. These results suggested that G870A polymor-
phismmight contribute to the increased risk in different tumor
type or ethnicity population. According to our recent knowl-
edge, only three studies have been conducted to examine the
associations between the G870A polymorphism and HCC
risks [8, 23, 24]. The control subjects used in these studies
were all recruited from the health examination individuals
without evidence of HBV infection. Since most HCC patients
in China have HBV infection and hepatic cirrhosis, it is im-
perative to explore association between G870A polymor-
phism and the risk of HBV-related HCC by using chronic
HBV infection or cirrhotic CHB patients as control
population.
In this study, we investigated the HCC tumor relevance of
G870A polymorphism in a relatively large cohort, with the
healthy control, CHB patients or cirrhotic CHB patients as
the control population. We found that the G870A genotype
had no association with the susceptibility of HBV-related
HCC in this Chinese cohort. This result is consistent with
two studies performed in a Taiwan or mainland Chinese pop-
ulation by Zhang et al. [23] and Hu et al. [24], which showed
no association between G870A genotype and HCC risk in a
Taiwan or mainland Chinese population by using healthy pop-
ulation as control. By contrast, the report of Akkiz et al. [8]
identified a significant association between the A allele and
the increased HCC risk in a Turkish population. Except the
ethnic difference, the specific etiological difference of HCC
may provide an alternative explanation of the above contra-
diction. Since chronic HBV infection is a well-known strong
risk factor for HCC, it is reasonable to assume that its strong
association with HCC may muffle the weak association of
G870A polymorphism. Indeed, our stratification analysis by
age revealed a weak association between AA genotype and
higher HCC risk in younger cirrhotic CHB patients (ages≤
50). Similar to our results, Hu et al. [24] also found that the
AG and AA genotypes were associated with an increased risk
of HCC among HBsAg-positive individuals. However, larger
well-designed studies are still required to evaluate the interac-
tion of G870A polymorphism with HCC risk.
CCND1 G870A polymorphism was thought to affect cy-
clin D1 variant expression in nonsmall cell lung cancer, head
and neck squamous cell carcinoma, and prostate cancer [20,
25, 26]. In our study, we found that both A and G alleles can
splice to form cyclin D1a or D1b, and the expression level of
cyclin D1a or cyclin D1b had no association with the G870A
genotype in HCC tumor, adjacent nontumor, and normal liver
tissues. Our findings is consistent with the results from lym-
phoma and esophageal cancers [13, 27], supporting the notion
that the alternative splicing of CCND1 gene also depends on
cell origin. It is interesting that both cyclin D1a and cyclin
D1b transcripts had more G allele than A allele in AG hetero-
zygous liver cells. One explanation is that G allele may have
higher transcript efficiency than A allele in liver cells.
Although cyclin D1 overexpression shows a close associ-
ation with malignancy, little is known about the status of cy-
clin D1a and cyclin D1b expression in HBV-related HCC. We
found that the expression of both cyclins D1a and D1b are
significantly lower in the tumor-derived specimens of HBV-
related HCC as compared with the adjacent nontumor tissues.
Fig. 3 Relationship between
cyclin D1a and cyclin D1b
expression in HCC tissues. a The
correlation of cyclin D1a and
cyclin D1b expression level in 45
cases tumor tissues was analyzed
by liner correction. b The
correlation of cyclin D1a and
cyclin D1b expression level in
nontumor tissues was analyzed as
in (a)
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This result is consistent with numbers of research which also
demonstrated that cyclin D1 was decreased in HCC samples
[28–30], while inconsistent with a recent study which showed
the overexpression of cyclin D1 in about 40 % of HCC
samples [31]. Since these studies did not distinguish whether
the HCC tissues have the background of HBV infection and
liver cirrhosis, the conflicting results may be due to the com-
plicated etiological mechanism of HCC. Interestingly, we also
Fig. 4 Epitopic expression of cyclin D1a and cyclin D1b promote the
cell proliferation in Huh-7 and LO2 cells. Huh-7 and LO2 cells were
transiently transfected with pFlex-cyclin D1a, pFlex-cyclin D1b, and
pFlex vector. Ectopic expression of cyclin D1 variants was detected by
Western blot analysis using Flag-tagged antibody (a). b The CCK-8 assay
was performed to measure the growth curve of Huh-7 and LO2 cells
transfected with plasmids as (a). All measurements were done in triplicate
and data are shown as the means±SD. P values<0.05 (*), <0.01 (**) or
<0.001 (***). c Cell cycle was detected by flow cytometry analysis in
Huh-7 and LO2 cells transfected with plasmids as (a)
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found that the cyclin D1 expression was significantly in-
creased in HCC tumor tissues without HBV infection
(Fig. S1), supporting the notion that the expression and func-
tion of cyclin D1 in HCCwithout HBV infection was different
to that with HBV infection. At present, the mechanism under-
lying the lower levels of cyclin D1 expression in HBV-related
HCC tissues is unknown. Previous studies have reported that
the viral proteins of HBV, such as HBx and HBsAg, could
upregulate cyclin D1 expression through activating Wnt, Erk,
and NF-κB pathways [32–34]. Moreover, studies on viral
protein expression in HCC showed that the HBx or HBsAg
expression level was higher in nontumor tissues as compared
with that in tumor tissues [33, 35]. Based on these findings, we
assumed that the downregulation of cyclin D1 in HBV-related
HCC tissues may be linked to the reduced HBx or HBsAg
expression. Further study should be performed to investigate
the specific expression pattern of each cyclin D1 variant and
the underlying mechanism of its downregulation in the HBV-
related HCC tissues.
In the case of HBV-related HCC, we noticed that the ex-
pression of both cyclins D1a and D1b was increased in adja-
cent nontumor cirrhotic tissues as compared with that in nor-
mal liver tissues. It has been reported that the cirrhosis regen-
erative nodules may progress along a well-described carcino-
genic pathway to become dysplastic nodules or hepatocellular
carcinomas [36]. Since our study have demonstrated that over-
expression of both cyclin D1a and cyclin D1b could promote
cell proliferation by accelerating the cell cycle, it is reasonable
to suppose a potential oncogenic role for both D1 variants
d u r i n g t h e p r o g r e s s i o n o f HBV- a s s o c i a t e d
hepatocarcinogenesis from as early as the precancerous cir-
rhotic stage. Then the next question to consider is that how
HCC tumor cells remain their uncontrolled proliferation with-
out cyclin D1 overexpression in HCC. It is known that cyclin
D1 promotes cell-cycle progression via binding to and activa-
tion of cyclin-dependent kinases 4 and 6 (CDK4/6). The cy-
clin D1/CDK complexes phosphorylate and inactivate the ret-
inoblastoma protein (Rb), thereby triggering E2F-dependent
transcription of genes required for S-phase entry [37]. There-
fore, the loss of the functional pRB also could keep driving
cell-cycle progression and proliferation independently of the
high cyclin D1 level. Indeed, other studies and our previous
aCGH data have identified a frequently functional loss of RB
gene in HBV-related HCC [38, 39].
Moreover, besides G870A polymorphism, it is now clear
from a number of studies that other factors, such as chromatin-
remodeling protein Brm, RNA-binding protein Sam68, and
Ewing’s sarcoma oncogene, may also modulate the expres-
sion of cyclin D1b [40–42]. Thus, the relative production of
cyclin D1b and cyclin D1a may reflect differences in the tu-
mors’ specific signaling pathways. However, we found that
the cyclin D1b/D1a ratio in HCC tumor tissues showed no
difference with that in adjacent nontumor tissues and normal
liver tissues. This finding is supported by our analyses of
linear relationship between cyclins D1a and D1b expression
in both tumor and nontumor tissues. Since the cyclins D1a and
D1b are transcribed from the same gene, these data indicated
that the expression patterns of cyclin D1b are similar to that of
cyclin D1a in liver tissues. Thus, the same mechanism under-
lying the regulation of both isoforms may exist in liver tissues.
In summary, the data herein demonstrated that the G870A
polymorphism is not a strong predictor of the HBV-related
HCC risk in Chinese population. The two variants were both
transcripted from A and G alleles, and neither cyclin D1a nor
cyclin D1b production was influenced by G870A genotype in
HCC. Both cyclins D1a and D1b could promote cell prolifer-
ation, which might contribute to the potential oncogenic role
of cyclin D1 variants during the precancerous cirrhotic stage
of HBV-associated hepatocarcinogenesis.
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